| pubmed-article:8151598 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8151598 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:8151598 | lifeskim:mentions | umls-concept:C0031676 | lld:lifeskim |
| pubmed-article:8151598 | lifeskim:mentions | umls-concept:C0008286 | lld:lifeskim |
| pubmed-article:8151598 | lifeskim:mentions | umls-concept:C0053358 | lld:lifeskim |
| pubmed-article:8151598 | lifeskim:mentions | umls-concept:C0162595 | lld:lifeskim |
| pubmed-article:8151598 | lifeskim:mentions | umls-concept:C1521970 | lld:lifeskim |
| pubmed-article:8151598 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8151598 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:8151598 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:8151598 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8151598 | pubmed:dateCreated | 1994-5-9 | lld:pubmed |
| pubmed-article:8151598 | pubmed:abstractText | To investigate the nature of the target epitope for human immunodeficiency virus (HIV) and chlorpromazine (CPZ) induced antiphospholipid antibodies (aPL) by evaluating the effect of the aPL cofactor (beta 2 glycoprotein I) on phospholipid binding and to compare this with known binding patterns of infection induced and autoimmune aPL. | lld:pubmed |
| pubmed-article:8151598 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8151598 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8151598 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8151598 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8151598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8151598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8151598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8151598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8151598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8151598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8151598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8151598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8151598 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8151598 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:8151598 | pubmed:issn | 0315-162X | lld:pubmed |
| pubmed-article:8151598 | pubmed:author | pubmed-author:LockshinM DMD | lld:pubmed |
| pubmed-article:8151598 | pubmed:author | pubmed-author:MorseJ HJH | lld:pubmed |
| pubmed-article:8151598 | pubmed:author | pubmed-author:ZarrabiM HMH | lld:pubmed |
| pubmed-article:8151598 | pubmed:author | pubmed-author:WenJJ | lld:pubmed |
| pubmed-article:8151598 | pubmed:author | pubmed-author:GharaviA EAE | lld:pubmed |
| pubmed-article:8151598 | pubmed:author | pubmed-author:SammaritanoL... | lld:pubmed |
| pubmed-article:8151598 | pubmed:author | pubmed-author:MiyawakiNN | lld:pubmed |
| pubmed-article:8151598 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8151598 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:8151598 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8151598 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8151598 | pubmed:pagination | 94-9 | lld:pubmed |
| pubmed-article:8151598 | pubmed:dateRevised | 2010-3-24 | lld:pubmed |
| pubmed-article:8151598 | pubmed:meshHeading | pubmed-meshheading:8151598-... | lld:pubmed |
| pubmed-article:8151598 | pubmed:meshHeading | pubmed-meshheading:8151598-... | lld:pubmed |
| pubmed-article:8151598 | pubmed:meshHeading | pubmed-meshheading:8151598-... | lld:pubmed |
| pubmed-article:8151598 | pubmed:meshHeading | pubmed-meshheading:8151598-... | lld:pubmed |
| pubmed-article:8151598 | pubmed:meshHeading | pubmed-meshheading:8151598-... | lld:pubmed |
| pubmed-article:8151598 | pubmed:meshHeading | pubmed-meshheading:8151598-... | lld:pubmed |
| pubmed-article:8151598 | pubmed:meshHeading | pubmed-meshheading:8151598-... | lld:pubmed |
| pubmed-article:8151598 | pubmed:meshHeading | pubmed-meshheading:8151598-... | lld:pubmed |
| pubmed-article:8151598 | pubmed:meshHeading | pubmed-meshheading:8151598-... | lld:pubmed |
| pubmed-article:8151598 | pubmed:meshHeading | pubmed-meshheading:8151598-... | lld:pubmed |
| pubmed-article:8151598 | pubmed:meshHeading | pubmed-meshheading:8151598-... | lld:pubmed |
| pubmed-article:8151598 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8151598 | pubmed:articleTitle | Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: effect of beta 2 glycoprotein I on binding to phospholipid. | lld:pubmed |
| pubmed-article:8151598 | pubmed:affiliation | Antiphospholipid Research Laboratory, New Orleans 70112. | lld:pubmed |
| pubmed-article:8151598 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8151598 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8151598 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8151598 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8151598 | lld:pubmed |
